Enteral Access Technologies secures £500K to scale DoubleCHEK

Liverpool-based Enteral Access Technologies (EAT) has raised £500,000 in a bridging round led by British Design Fund, with participation from existing investors.

Founded in 2018, EAT develops tools to
make nasogastric and orogastric tube placement safer and simpler. Its flagship
product, DoubleCHEK, combines CO₂ and pH measurement in a single device to
reduce the risk of misplacement and enable quicker, more accurate tube placement
across care settings without special equipment or tube types.

By addressing misplacement and
radiation-exposure risks associated with current insertion and confirmation
methods, EAT aims to improve patient safety and streamline workflows.

EAT is seeing growing adoption in the
UK as providers align with updated guidance supporting combined CO₂ and pH
verification. Internationally, EAT is also scaling rapidly.

In the United States, interest
increased after a leading children’s hospital adopted DoubleCHEK in January and
further accelerated following the withdrawal of a comparable product. In
Europe, rollout is underway, with Italy among the early adopters. Repeat orders
and strong initial uptake indicate emerging traction as hospitals seek safer,
more reliable enteral access solutions.

Commenting on the new round, George
Gallagher, CEO of EAT, said that the investment demonstrates strong backing for
the company’s mission to enhance patient safety globally. He added that growing
interest in DoubleCHEK reinforces EAT’s focus on expanding access to safer
enteral technologies.

With this new funding, the
company will advance the development and accelerate the international rollout
of its enteral access patient safety device.